Synthesis and anticancer activities of 6-amino amonafide derivatives

@article{Norton2008SynthesisAA,
  title={Synthesis and anticancer activities of 6-amino amonafide derivatives},
  author={John Thomas Norton and Mark A. Witschi and Lynn Luong and Akane Kawamura and Supurna Ghosh and M. Sharon Stack and Edith Sim and Michael J. Avram and Daniel H. Appella and Sui Huang},
  journal={Anti-Cancer Drugs},
  year={2008},
  volume={19},
  pages={23-36}
}
Amonafide is a DNA intercalator and topoisomerase II inhibitor in clinical development for the treatment of neoplastic diseases. Amonafide contains a free arylamine, which causes it to be metabolized in humans by N-acetyl transferase-2 (NAT2) into a toxic form. To eliminate the NAT2 acetylation of amonafide while retaining the anticancer properties, we have synthesized nine derivatives that are structurally similar to amonafide that should not be acetylated. Eight derivatives have arylamines at… 
Synthesis, cytotoxicity, DNA binding and topoisomerase II inhibition of cassiarin A derivatives.
TLDR
These cassiarin A derivatives showed lower toxicity to normal cells, WI-38 than amonafide therefore they are potential lead compounds to be further developed as new anticancer agents.
Is an Efficacious and Minimally Toxic Amonafide Derivative in Murine Models of Human Cancer 1
TLDR
The studies presented here demonstrate that MEAN is much less toxic than amonafide or AN in mouse models of human liver and gastric cancers while being equally efficacious in vivo and inhibiting cancer cells through similar mechanisms.
Synthesis and evaluation of novel amonafide–polyamine conjugates as anticancer agents
TLDR
In vivo trials on three H22 tumor transplant models demonstrated that the combination of 6k and aspirin markedly improved the efficacy in terms of inhibitive effect, pulmonary metastasis, and extension of the life span.
Anticancer Activity and Topoisomerase II Inhibition of Naphthalimides with ω-Hydroxylalkylamine Side-Chains of Different Lengths.
TLDR
1,8-Naphthalimides modified in various positions of chromophore, provided an effective method for enhancing their anticancer activity and reducing undesirable toxic effects and influence of the substitution pattern on the ability to inhibit Topo II activity was observed.
Evaluation of apoptotic effect of cyclic imide derivatives on murine B16F10 melanoma cells.
TLDR
Results confirm that the percentage of B16F10 cells observed in the sub G0/G1 phase were undergoing apoptosis, and suggested promising applications, especially for the prototype compound 4.
Methoxyethylamino-numonafide is an efficacious and minimally toxic amonafide derivative in murine models of human cancer.
TLDR
The studies presented here demonstrate that MEAN is much less toxic than amonafide or AN in mouse models of human liver and gastric cancers while being equally efficacious in vivo and inhibiting cancer cells through similar mechanisms.
Induction of apoptosis and suppression of ERCC1 expression by the potent amonafide analogue 8-c in human colorectal carcinoma cells
TLDR
The findings suggest that 8-c has a strong potential to be developed as a new antitumor agent for the treatment of multi-drug-resistant colon cancer cells, and is worthy of further studies.
Novel naphthalimide derivatives as potential apoptosis-inducing agents: design, synthesis and biological evaluation.
A series of novel naphthalimide derivatives with flexible alkyl/aryl moieties were designed and synthesized. Their antitumor activities were evaluated against HeLa, A549, P388, HL-60, MCF-7, HCT-8
Synthesis, anticancer activity and DNA-binding properties of novel 4-pyrazolyl-1,8-naphthalimide derivatives.
TLDR
A novel series of 4-pyrazolyl-1,8-naphthalimide derivatives have been designed and facilely synthesized and results indicated that compound 4i as the DNA-intercalating agent exhibited middle binding affinity with CT-DNA.
Naphthalimides and analogues as antitumor agents: A review on molecular design, bioactivity and mechanism of action
Abstract In this review, we retrospect our progress in biological active naphthalimide and analogues as antitumor agents in the past 20 years. On one hand, various derivations in naphthalimide
...
1
2
3
4
...

References

SHOWING 1-10 OF 30 REFERENCES
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
TLDR
A pharmacodynamic model based on acetylator phenotype, pretreatment white blood cell count, and gender has been proposed for dose individualization and the strategy adopted for amonafide is a model for future investigations in pharmacogenetics, although amonAFide is no longer in clinical development.
Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening.
TLDR
The expression and characterisation of shNAT2 is described and also purified recombinant human NAT1 and NAT2 are described, including the use of the assay to explore the substrate specificities of each of the enzymes.
New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties.
TLDR
Amonafide- and elinafide-related mono and bisintercalators modified by the introduction of a pi-excedent furan or thiophene ring fused to the naphthalimide moiety are synthesized and it is proposed that the DNA binding process does not depend on the electronic nature of the fused heterocycle.
Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans.
TLDR
Two of the primary metabolites, the N(N5)-acetyl and N'(N1)-oxide metabolites of Amonafide, were tested in vitro for cytotoxicity against P388 murine leukemia cells and the N-acetyl metabolite was observed to be only slightly less cytotoxic than the parent compound.
In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia.
TLDR
Rapid cellular uptake of nafidimide, with low retention at the end of exposure and rapid rejoining of DNA SSB suggest that prolonged cellular exposure may be necessary for optimal antitumor effect, and in vitro cloning data suggest that nafodimide may be a therapeutic option for patients with leukemia resistant to m-AMSA.
Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs.
TLDR
Treatment of SV40-infected monkey cells with amonafide (benzisoquinolinedione), an intercalative antitumor drug, resulted in rapid accumulation of linearized intracellular SV40 DNA molecules that were protein linked, and unwinding measurements indicate that amonfide is a DNA intercalator.
In vitro cytotoxicity and DNA damage production in Chinese hamster ovary cells and topoisomerase II inhibition by 2-[2'- (dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[ de,h]isoquinoline-1,3-diones with substitutions at the 6 and 7 positions (azonafides)
TLDR
The results suggest that the azonafides inhibit Topo II to cause protein-associated strand breaks and impaired DNA and RNA synthesis and other mechanisms may also be operant, especially with the more potent dimethylamino ethyl substituted analogs.
Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage.
TLDR
The results suggest that the exceptionally high sequence specificity of amonafide is the result of optimal drug interactions with both the two enzyme subunits.
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
  • M. Costanza, D. Berry, +7 authors A. Lyss
  • Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1995
TLDR
It is concluded that amonafide is somewhat active in previously untreated breast cancer patients and there may be a steep dose-response curve, based on the significant correlation between myelosuppression and response.
ATP-bound Topoisomerase II as a Target for Antitumor Drugs*
TLDR
Using Lac repressor-operator complexes as roadblocks, it is shown that ATP-bound TOP2 acts as a circular clamp capable of entering DNA ends and sliding on unobstructed duplex DNA.
...
1
2
3
...